Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.

Cwynarski K, Marzolini MAV, Barrington SF, Follows G, Illidge T, Stern S, Davies A; British Society for Haematology Guidelines.

Br J Haematol. 2019 Jan 4. doi: 10.1111/bjh.15731. [Epub ahead of print] No abstract available.

PMID:
30609016
2.

Targeting MEK in vemurafenib-resistant hairy cell leukemia.

Caeser R, Collord G, Yao WQ, Chen Z, Vassiliou GS, Beer PA, Du MQ, Scott MA, Follows GA, Hodson DJ.

Leukemia. 2019 Feb;33(2):541-545. doi: 10.1038/s41375-018-0270-2. Epub 2018 Oct 19. No abstract available.

3.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP.

Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6. No abstract available.

4.

Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.

Schuh AH, Parry-Jones N, Appleby N, Bloor A, Dearden CE, Fegan C, Follows G, Fox CP, Iyengar S, Kennedy B, McCarthy H, Parry HM, Patten P, Pettitt AR, Ringshausen I, Walewska R, Hillmen P.

Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460. [Epub ahead of print] No abstract available.

PMID:
30009455
5.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

6.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.

PMID:
28976790
7.

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T.

Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14793. [Epub ahead of print] No abstract available.

PMID:
28643365
8.

Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.

Varghese AM, Howard DR, Pocock C, Rawstron AC, Follows G, McCarthy H, Dearden C, Fegan C, Milligan D, Smith AF, Gregory W, Hillmen P; NCRI CLL Sub-Group.

Br J Haematol. 2017 Feb;176(4):573-582. doi: 10.1111/bjh.14342. Epub 2016 Dec 29.

9.

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.

Kazianka L, Drucker C, Skrabs C, Thomas W, Melchardt T, Struve S, Bergmann M, Staber PB, Porpaczy E, Einberger C, Heinz M, Hauswirth A, Raderer M, Pabinger I, Thalhammer R, Egle A, Wendtner CM, Follows G, Hoermann G, Quehenberger P, Jilma B, Jaeger U.

Leukemia. 2017 May;31(5):1117-1122. doi: 10.1038/leu.2016.316. Epub 2016 Nov 2.

10.

Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones.

Bashford-Rogers RJ, Palser AL, Hodkinson C, Baxter J, Follows GA, Vassiliou GS, Kellam P.

Exp Hematol. 2017 Feb;46:31-37.e10. doi: 10.1016/j.exphem.2016.09.010. Epub 2016 Sep 28.

11.

Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.

Speedy HE, Kinnersley B, Chubb D, Broderick P, Law PJ, Litchfield K, Jayne S, Dyer MJS, Dearden C, Follows GA, Catovsky D, Houlston RS.

Blood. 2016 Nov 10;128(19):2319-2326. doi: 10.1182/blood-2016-01-695692. Epub 2016 Aug 15.

12.

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.

PMID:
27378086
13.

The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit.

Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos NF, Liu H, Kocialkowski S, Wang M, Huang Y, Worrillow L, Goodlad J, Buxton J, Neat M, Fields P, Wilkins B, Grant JW, Wright P, Ei-Daly H, Follows GA, Roman E, Watkins AJ, Johnson PW, Jack A, Du MQ.

J Pathol Clin Res. 2015 Mar 30;1(3):125-133. eCollection 2015 Jul.

14.

Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.

Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G, Rule SA.

Br J Haematol. 2017 Jul;178(2):327-329. doi: 10.1111/bjh.14122. Epub 2016 May 16. No abstract available.

PMID:
27197509
15.

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.

Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T.

Blood. 2016 Jun 9;127(23):2847-55. doi: 10.1182/blood-2015-11-680074. Epub 2016 Mar 3.

16.

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.

Rule S, Smith P, Johnson PW, Bolam S, Follows G, Gambell J, Hillmen P, Jack A, Johnson S, Kirkwood AA, Kruger A, Pocock C, Seymour JF, Toncheva M, Walewski J, Linch D.

Haematologica. 2016 Feb;101(2):235-40. doi: 10.3324/haematol.2015.128710. Epub 2015 Nov 26.

17.

Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.

Wagner M, Oelsner M, Moore A, Götte F, Kuhn PH, Haferlach T, Fiegl M, Bogner C, Baxter EJ, Peschel C, Follows GA, Ringshausen I.

Blood. 2016 Jan 28;127(4):436-48. doi: 10.1182/blood-2015-05-646935. Epub 2015 Oct 27.

18.

Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: A Haematologist's Perspective.

Follows GA.

Clin Oncol (R Coll Radiol). 2015 Aug;27(8):457-9. doi: 10.1016/j.clon.2015.05.008. Epub 2015 Jun 10. No abstract available.

PMID:
26071896
19.

Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C.

Mifsud B, Tavares-Cadete F, Young AN, Sugar R, Schoenfelder S, Ferreira L, Wingett SW, Andrews S, Grey W, Ewels PA, Herman B, Happe S, Higgs A, LeProust E, Follows GA, Fraser P, Luscombe NM, Osborne CS.

Nat Genet. 2015 Jun;47(6):598-606. doi: 10.1038/ng.3286. Epub 2015 May 4.

PMID:
25938943
20.

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, Bolli N, Grove C, Moody S, Escudero-Ibarz L, Gundem G, Brugger K, Xue X, Mi E, Bench A, Scott M, Liu H, Follows G, Robles EF, Martinez-Climent JA, Oscier D, Watkins AJ, Du MQ.

Leukemia. 2015 May;29(5):1177-85. doi: 10.1038/leu.2014.330. Epub 2014 Nov 27.

PMID:
25428260
21.

Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods.

Bashford-Rogers RJ, Palser AL, Idris SF, Carter L, Epstein M, Callard RE, Douek DC, Vassiliou GS, Follows GA, Hubank M, Kellam P.

BMC Immunol. 2014 Aug 5;15:29. doi: 10.1186/s12865-014-0029-0.

22.

Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.

Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G.

J Clin Oncol. 2014 Jun 10;32(17):1782-91. doi: 10.1200/JCO.2013.52.2631. Epub 2014 May 12.

PMID:
24821885
23.

Guidelines for the first line management of classical Hodgkin lymphoma.

Follows GA, Ardeshna KM, Barrington SF, Culligan DJ, Hoskin PJ, Linch D, Sadullah S, Williams MV, Wimperis JZ; British Committee for Standards in Haematology.

Br J Haematol. 2014 Jul;166(1):34-49. doi: 10.1111/bjh.12878. Epub 2014 Apr 9. No abstract available.

PMID:
24712411
24.

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S, Pocock CF.

J Clin Oncol. 2014 Apr 20;32(12):1236-41. doi: 10.1200/JCO.2013.49.6547. Epub 2014 Mar 17.

25.

Hairy cell leukemia - immunotargets and therapies.

Basheer F, Bloxham DM, Scott MA, Follows GA.

Immunotargets Ther. 2014 Jun 24;3:107-20. doi: 10.2147/ITT.S31425. eCollection 2014. Review.

26.

Pitfalls in the diagnosis of anaplastic large cell lymphoma with a small cell pattern.

Grigoropoulos RL, Wright P, van T'veer MB, Scott MA, Follows GA.

Case Rep Hematol. 2013;2013:840253. doi: 10.1155/2013/840253. Epub 2013 Oct 10.

27.

Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations.

Bashford-Rogers RJ, Palser AL, Huntly BJ, Rance R, Vassiliou GS, Follows GA, Kellam P.

Genome Res. 2013 Nov;23(11):1874-84. doi: 10.1101/gr.154815.113. Epub 2013 Jun 6.

28.

Leukaemia update. Part 2: managing patients with leukaemia in the community.

Grigoropoulos NF, Petter R, Van 't Veer MB, Scott MA, Follows GA.

BMJ. 2013 Apr 9;346:f1932. doi: 10.1136/bmj.f1932. Review. No abstract available.

PMID:
23571739
29.

Leukaemia update. Part 1: diagnosis and management.

Grigoropoulos NF, Petter R, Van 't Veer MB, Scott MA, Follows GA.

BMJ. 2013 Mar 28;346:f1660. doi: 10.1136/bmj.f1660. Review. No abstract available.

PMID:
23538920
30.

Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.

Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H, Bench A, Wright P, Van't Veer MB, Scott MA.

Br J Haematol. 2013 Apr;161(1):150-3. doi: 10.1111/bjh.12201. Epub 2012 Dec 29. No abstract available.

PMID:
23278307
31.

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.

Oscier D, Dearden C, Eren E, Fegan C, Follows G, Hillmen P, Illidge T, Matutes E, Milligan DW, Pettitt A, Schuh A, Wimperis J; British Committee for Standards in Haematology.

Br J Haematol. 2012 Dec;159(5):541-64. doi: 10.1111/bjh.12067. Epub 2012 Oct 11. No abstract available. Erratum in: Br J Haematol. 2013 Mar;160(6):868. Dosage error in article text. Br J Haematol. 2013 Apr;161(1):154. Erem, Efrem [corrected to Eren, Efrem].

PMID:
23057493
32.

Is this the end of radiotherapy in early hodgkin lymphoma?

Maund IF, Williams MV, Hoskin PJ, Follows GA.

Clin Oncol (R Coll Radiol). 2013 Jan;25(1):46-8. doi: 10.1016/j.clon.2012.07.007. Epub 2012 Jul 25. No abstract available.

PMID:
22841148
33.

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P.

J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9.

PMID:
22493413
34.

Primary testicular lymphoma.

Ahmad SS, Idris SF, Follows GA, Williams MV.

Clin Oncol (R Coll Radiol). 2012 Jun;24(5):358-65. doi: 10.1016/j.clon.2012.02.005. Epub 2012 Mar 17. Review.

PMID:
22424983
35.

Mapping and functional characterisation of a CTCF-dependent insulator element at the 3' border of the murine Scl transcriptional domain.

Follows GA, Ferreira R, Janes ME, Spensberger D, Cambuli F, Chaney AF, Kinston SJ, Landry JR, Green AR, Göttgens B.

PLoS One. 2012;7(3):e31484. doi: 10.1371/journal.pone.0031484. Epub 2012 Mar 1.

36.

Richter transformation: clonal identity does not indicate a linear disease progression.

Liu H, Yan Q, Nuako-Bandoh B, Grigoropoulos N, Huang Y, Follows G, Grant J, Lawton H, Wright P, Du MQ.

Br J Haematol. 2012 Apr;157(1):136-9. doi: 10.1111/j.1365-2141.2011.08917.x. Epub 2011 Nov 3. No abstract available.

PMID:
22050709
37.

High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies.

Boyd EM, Bench AJ, van 't Veer MB, Wright P, Bloxham DM, Follows GA, Scott MA.

Br J Haematol. 2011 Dec;155(5):609-12. doi: 10.1111/j.1365-2141.2011.08868.x. Epub 2011 Sep 13.

PMID:
21910720
38.

Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme.

Chowdhury O, Varghese A, Pattinson J, Carrington P, Bloor A, Follows GA, Hillmen P, Schuh A.

Br J Haematol. 2011 Nov;155(4):519-21. doi: 10.1111/j.1365-2141.2011.08711.x. Epub 2011 May 12. No abstract available.

PMID:
21564074
39.

Bilateral irreversible blindness in leukaemic meningitis: cause or cure?

Tziotzios C, Follows G, Sarkies N, Crawley C.

Ann Hematol. 2011 Dec;90(12):1487-8. doi: 10.1007/s00277-011-1202-7. Epub 2011 Mar 4. No abstract available.

PMID:
21373928
40.

Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells.

Leddin M, Perrod C, Hoogenkamp M, Ghani S, Assi S, Heinz S, Wilson NK, Follows G, Schönheit J, Vockentanz L, Mosammam AM, Chen W, Tenen DG, Westhead DR, Göttgens B, Bonifer C, Rosenbauer F.

Blood. 2011 Mar 10;117(10):2827-38. doi: 10.1182/blood-2010-08-302976. Epub 2011 Jan 14. Erratum in: Blood. 2011 May 26;117(21):5783.

41.

Massive genomic rearrangement acquired in a single catastrophic event during cancer development.

Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ.

Cell. 2011 Jan 7;144(1):27-40. doi: 10.1016/j.cell.2010.11.055.

42.

cis-Regulatory remodeling of the SCL locus during vertebrate evolution.

Göttgens B, Ferreira R, Sanchez MJ, Ishibashi S, Li J, Spensberger D, Lefevre P, Ottersbach K, Chapman M, Kinston S, Knezevic K, Hoogenkamp M, Follows GA, Bonifer C, Amaya E, Green AR.

Mol Cell Biol. 2010 Dec;30(24):5741-51. doi: 10.1128/MCB.00870-10. Epub 2010 Oct 18.

43.

Incidental pulmonary emboli in lymphoma patients are associated with aggressive disease and poor prognosis.

Grigoropoulos NF, Shaw AS, Hampson FA, Baglin TP, Follows GA.

J Thromb Haemost. 2010 Dec;8(12):2835-6. doi: 10.1111/j.1538-7836.2010.04061.x. No abstract available.

44.

Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5.

Walter K, Cockerill PN, Barlow R, Clarke D, Hoogenkamp M, Follows GA, Richards SJ, Cullen MJ, Bonifer C, Tagoh H.

Oncogene. 2010 May 20;29(20):2927-37. doi: 10.1038/onc.2010.56. Epub 2010 Mar 8.

PMID:
20208555
45.

Platelet satellitism.

Padayatty J, Grigoropoulos N, Gilligan D, Follows GA.

Eur J Haematol. 2010 Apr;84(4):366. doi: 10.1111/j.1600-0609.2009.01386.x. Epub 2009 Nov 26. No abstract available.

PMID:
20002169
46.

Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma.

Zandi MS, Irani SR, Follows G, Moody AM, Molyneux P, Vincent A.

Neurology. 2009 Dec 8;73(23):2039-40. doi: 10.1212/WNL.0b013e3181c55e9b. No abstract available.

PMID:
19996080
47.

Incidental finding of lymphocytosis in an asymptomatic patient.

Grove CS, Follows GA, Erber WN.

BMJ. 2009 Jun 10;338:b2119. doi: 10.1136/bmj.b2119. No abstract available.

PMID:
19515711
48.

Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?

Todd T, Raj S, Camilleri D, Stafford G, Bulusu R, Follows G, Williams M, Marcus R.

Ann Hematol. 2009 Nov;88(11):1107-12. doi: 10.1007/s00277-009-0734-6. Epub 2009 May 6.

PMID:
19418054
49.

Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors.

Landry JR, Bonadies N, Kinston S, Knezevic K, Wilson NK, Oram SH, Janes M, Piltz S, Hammett M, Carter J, Hamilton T, Donaldson IJ, Lacaud G, Frampton J, Follows G, Kouskoff V, Göttgens B.

Blood. 2009 Jun 4;113(23):5783-92. doi: 10.1182/blood-2008-11-187757. Epub 2009 Jan 26.

50.

Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.

Zhao R, Follows GA, Beer PA, Scott LM, Huntly BJ, Green AR, Alexander DR.

N Engl J Med. 2008 Dec 25;359(26):2778-89. doi: 10.1056/NEJMoa0804953.

Supplemental Content

Loading ...
Support Center